ARS Pharmaceuticals (SPRY) Receivables - Net (2024 - 2026)

ARS Pharmaceuticals has reported Receivables - Net for 3 years, with the latest figure at $28.7 million in Q1 2026.

• Quarterly Receivables - Net rose 208.09% year-over-year to $28.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.7 million (up 208.09% YoY) and the FY2025 annual result came in at $25.3 million, up 210.06% from the prior year.
• Receivables - Net rose to $28.7 million in Q1 2026 per SPRY's latest filing, from $25.3 million in the prior quarter.
• Over five years, Receivables - Net peaked at $36.5 million in Q3 2025 and troughed at $773000.0 in Q3 2024.
• A 3-year average of $19.1 million and a median of $25.1 million in 2025 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net soared 4615.52% in 2025, then jumped 208.09% in 2026.
• Over 3 years, Receivables - Net stood at $8.2 million in 2024, then jumped by 210.06% to $25.3 million in 2025, then advanced by 13.08% to $28.7 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $28.7 million, $25.3 million, and $36.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.